These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35362346)

  • 21. Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    Lebrun-Frenay C; Moulignier A; Pierrot-Deseilligny C; Benrabah R; Moreau T; Lubetzki C; Monchecourt F;
    J Neurol; 2019 Apr; 266(4):888-901. PubMed ID: 30730008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
    Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
    BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate.
    Ziemssen T; Gilgun-Sherki Y
    BMC Neurol; 2015 Oct; 15():189. PubMed ID: 26450155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].
    Boyko AN; Lashch NY; Sharanova SN; Zakharova MN; Trifonova OV; Simaniv TO; Lysogorskaya EV; Guryanova OE; Kotov SV; Iakushina TI; Lizhdvoy VY; Belova YA; Khabirov FA; Babicheva NN; Khaibullin TI; Granatov EV; Averyanova LA; Sazonov DV; Odinak MM; Trinitatsky YV; Tsukurova LA; Sergeeva AI; Ivanov RA; Shustova MS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10 Pt 2):61-67. PubMed ID: 28139613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of adverse events in recent randomized clinical trials for dimethyl fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
    Zagmutt FJ; Carroll CA
    Int J Neurosci; 2015; 125(11):798-807. PubMed ID: 25387069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
    Zecca C; Mainetti C; Blum R; Gobbi C
    BMC Neurol; 2015 Dec; 15():249. PubMed ID: 26630967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disability progression
    von Wyl V; Benkert P; Moser A; Lorscheider J; Décard B; Hänni P; Lienert C; Kuhle J; Derfuss T; Kappos L; Yaldizli Ö
    Mult Scler; 2021 Mar; 27(3):439-448. PubMed ID: 32463336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
    Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
    J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
    Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
    Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.
    Johnson KP
    Expert Rev Neurother; 2012 Apr; 12(4):371-84. PubMed ID: 22449210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Evolving Mechanisms of Action of Glatiramer Acetate.
    Prod'homme T; Zamvil SS
    Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29440323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.
    Cutter G; Veneziano A; Grinspan A; Al-Banna M; Boyko A; Zakharova M; Maida E; Pasic MB; Gandhi SK; Everts R; Cordioli C; Rossi S
    Mult Scler Relat Disord; 2019 Aug; 33():13-21. PubMed ID: 31132664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.